摘要
目的探讨大肠埃希菌尿路感染的临床发病特点和对抗菌药物的耐药情况。方法对2008年5月至2009年5月尿路感染患者尿培养分离出的48株大肠埃希菌进行耐药性分析,用纸片扩散法表型确证试验检测超广谱β-内酰胺酶(ESBLs)。结果检出产ESBLs大肠埃希菌13株,检出率27.08%;产ESBLs大肠埃希菌对碳青霉烯类(亚胺培南)及β-内酰胺酶抑制剂复合物、阿米卡星耐药性较低,在7.6%～23.0%之间,其余抗菌药物都产生较高的耐药性。结论重视产ESBLs大肠埃希菌的检测,根据药敏试验结果合理用药,碳青霉烯类(亚胺培南)、及β-内酰胺酶抑制剂复合物、阿米卡星是目前治疗产ESBLs大肠埃希菌的有效抗菌药物。
Objective To investigate the clinical characteristic and antimicrobial resistance in patients with urinary tract infected by escherichia coli. Methods Drug resistances of 48 escherichia coli strains collected from the patients with urinary tract infection from May 2008 to May 2009 were analyzed, and the extended speetruβ-laetamase （ESBLs） were identified by means of disc agar diffusion method. Results Among the isolated β strains of ESBLs producing escherichia coli（27.08）, the resistant rate of ESBLs producing escherichia coli to carbapenem（imipenem- cilastatin）, complex antibiotics containing β-lactamases inhibitor and amikacin was relatively low （0--23.0 %）, while the resistant rate to other antimicrobial drugs was higher. Conclusion It is very important to determine the ESBLs producing escherichia coll. Correctly selecting antimicrobial drugs for the treatment of the infection diseases is conducted according to the results of susceptibility tests. The effective antimicrobial drugs to the infections caused by ESBLs producing escheriehia coli are earbapenem,complex antibiotics containing β-lactamases inhibitor and amikacin.
出处
《检验医学与临床》
CAS
2009年第22期1895-1896,1898,共3页
Laboratory Medicine and Clinic
